{"prompt": "['Product: MK-3475', '107', 'Protocol/Amendment No.: 604-09', '8.6.1.3 Objective Response Rate', 'The ORR is defined as the proportion of subjects who achieve a best objective response of', 'PR or CR.', \"Stratified Miettinen and Nurminen's method will be used for comparison of ORR between\", 'the treatment groups. The difference in ORR and its 95% CI from the stratified Miettinen and', 'Nurminen method with strata weighting by sample size will be provided. The same', 'stratification factors used for randomization (see Section 5.4) will be used as stratification', 'factors in the analysis.', '8.6.1.4 Duration of Response', 'For subjects who demonstrate CR or PR, DOR is defined as the time from first documented', 'evidence of CR or PR until disease progression or death due to any cause, whichever occurs', 'first. Censoring rules for DOR are summarized in Table 12. DOR will be assessed by BICR', 'per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of', '5 target lesions per organ.', 'For each DOR analysis, a corresponding summary of the reasons responding subjects are', 'censored will also be provided. Subjects who are alive, have not progressed, have not', 'initiated new anti-cancer treatment, have not been determined to be lost to follow-up, and', 'have had a disease assessment within ~ 5 months of the data cutoff date are considered', 'ongoing responders at the time of analysis. If a subject meets multiple criteria for censoring,', 'the censoring criterion that occurs earliest will be applied.', 'Table 12 Censoring Rules for Duration of Response', 'Date of', 'Situation', 'Outcome', 'Progression or Censoring', 'No progression nor death, no new anti-', 'Last adequate disease', 'Censor', 'cancer therapy initiated', 'assessment', '(non-event)', 'No progression nor death, new anti-', 'Last adequate disease', 'Censor', 'cancer therapy initiated', 'assessment before new anti-', '(non-event)', 'cancer therapy initiated', 'Death or progression after', 'Last adequate disease', 'Censor', '>2 consecutive missed disease', 'assessment prior to >2 missed', '(non-event)', 'assessments', 'adequate disease assessments', 'Death or progression after 1 missed', 'Progressive disease or death', 'End of response', 'adequate disease assessments', '(Event)', 'Note: A missed disease assessment includes any assessment that is not obtained or is considered inadequate', 'for evaluation of response.', 'A summary of the primary analysis strategy for the primary and secondary efficacy endpoints', 'is provided in Table 13.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '108', 'Protocol/Amendment No.: 604-09', 'Table 13 Efficacy Analysis Methods for Primary and Secondary Efficacy Endpoints', 'Endpoint/Variable', 'Statistical Method', 'Analysis Population', '(Description, Time Point)', 'Missing Data Approach', 'Primary Analyses:', 'PFS (RECIST 1.1*) by', 'Testing: Stratified Log-', 'ITT', 'Censored according to', 'BICR', 'rank test', 'rules in Table 11', 'Estimation: Stratified Cox', \"model with Efron's tie\", 'handling method', 'os', 'Testing: Stratified Log-', 'ITT', 'Censored at last known', 'rank test', 'alive date', 'Estimation: Stratified Cox', \"model with Efron's tie\", 'handling method', 'Secondary Analyses:', 'ORR (RECIST 1.1*) by', 'Testing: Stratified', 'ITT', 'Subjects with missing', 'BICR', 'Miettinen and Nurminen', 'data are considered non-', 'method', 'responders', 'DOR (RECIST 1.1*) by', 'Summary statistics using', 'All responders in ITT', 'Non-responders are', 'BICR', 'Kaplan-Meier method', 'excluded in analysis', '*As assessed by BICR per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum', 'of 5 target lesions per organ', '8.6.2 Statistical Methods for Safety Analyses', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs and laboratory tests.', 'The analysis of safety results will follow a tiered approach (Table 14). The tiers differ with', 'respect to the analyses that will be performed. Safety parameters or AEs of special interest', 'that are identified a priori constitute \"Tier 1\" safety endpoints that will be subject to', 'inferential testing for statistical significance with p-values and 95% CIs provided for', 'between-group comparisons. Other safety parameters will be considered Tier 2 or Tier 3.', 'Tier 2 parameters will be assessed via point estimates with 95% CIs provided for', 'between-group comparisons; only point estimates by treatment group are provided for Tier 3', 'safety parameters.', 'Adverse events of special interest (AEOSIs) that are immune-mediated or potentially', 'immune-mediated are well documented and will be evaluated separately; however, these', 'events have been characterized consistently throughout the pembrolizumab clinical', 'development program and determination of statistical significance is not expected to add', 'value to the safety evaluation. Further, pembrolizumab added to platinum doublets studied', 'thus far have not been found to impact safety, and in an ongoing Phase 1 clinical trial, the', 'chemotherapeutic regimen used here with pembrolizumab has not led to increased toxicity', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}